271 related articles for article (PubMed ID: 16510063)
1. When should COX-2 selective NSAIDs be used for osteoarthritis and rheumatoid arthritis?
Lo V; Meadows SE; Saseen J
J Fam Pract; 2006 Mar; 55(3):260-2. PubMed ID: 16510063
[TBL] [Abstract][Full Text] [Related]
2. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ
Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785
[TBL] [Abstract][Full Text] [Related]
4. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
5. Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective.
Hochberg MC
Am J Manag Care; 2002 Nov; 8(17 Suppl):S502-17. PubMed ID: 12458820
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
Dajani EZ; Islam K
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
[TBL] [Abstract][Full Text] [Related]
7. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.
Lee MC; Lee S; Suh DC; Kim J; Kong SX;
Curr Med Res Opin; 2003; 19(7):597-602. PubMed ID: 14606981
[TBL] [Abstract][Full Text] [Related]
8. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
Hur C; Chan AT; Tramontano AC; Gazelle GS
Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
[TBL] [Abstract][Full Text] [Related]
9. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
Tannenbaum H; Bombardier C; Davis P; Russell AS;
J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
[TBL] [Abstract][Full Text] [Related]
10. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
Kean WF; Buchanan WW
Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389
[TBL] [Abstract][Full Text] [Related]
11. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
12. What are the risks of long-term NSAIDs and COX-2 inhibitors?
DeBisschop M
J Fam Pract; 2003 Mar; 52(3):199-200. PubMed ID: 12620173
[TBL] [Abstract][Full Text] [Related]
13. Osteoarthritis therapy--are there still unmet needs?
Laufer S
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i9-15. PubMed ID: 14752170
[TBL] [Abstract][Full Text] [Related]
14. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
15. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
Moore RA; Derry S; Phillips CJ; McQuay HJ
BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
[TBL] [Abstract][Full Text] [Related]
16. Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).
Cox ER; Motheral B; Mager D
Am J Manag Care; 2003 Dec; 9(12):785-94. PubMed ID: 14712755
[TBL] [Abstract][Full Text] [Related]
17. The NSAID dilemma: managing osteoarthritis in high-risk patients.
Roth SH; Anderson S
Phys Sportsmed; 2011 Sep; 39(3):62-74. PubMed ID: 22030942
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan.
Sakamoto C; Soen S
Digestion; 2011; 83(1-2):108-23. PubMed ID: 21042022
[TBL] [Abstract][Full Text] [Related]
19. COXIBs and non-selective NSAIDs in the gastroenterological setting: what should patients and physicians do?
Lazzaroni M; Battocchia A; Bianchi Porro G
Dig Liver Dis; 2007 Jun; 39(6):589-96. PubMed ID: 17459794
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
Huang WF; Hsiao FY; Wen YW; Tsai YW
Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]